Int. J. Mol. Sci. 2011, 12(10), 7163-7185; doi:10.3390/ijms12107163

Mitochondrial Peroxiredoxin III is a Potential Target for Cancer Therapy

email, email, email, email, email, email, email and * email
Received: 29 July 2011; in revised form: 30 September 2011 / Accepted: 20 October 2011 / Published: 21 October 2011
(This article belongs to the Special Issue Oxidative Stress and Mitochondria)
View Full-Text   |   Download PDF [544 KB, uploaded 19 June 2014]
Abstract: Mitochondria are involved either directly or indirectly in oncogenesis and the alteration of metabolism in cancer cells. Cancer cells contain large numbers of abnormal mitochondria and produce large amounts of reactive oxygen species (ROS). Oxidative stress is caused by an imbalance between the production of ROS and the antioxidant capacity of the cell. Several cancer therapies, such as chemotherapeutic drugs and radiation, disrupt mitochondrial homeostasis and release cytochrome c, leading to apoptosome formation, which activates the intrinsic pathway. This is modulated by the extent of mitochondrial oxidative stress. The peroxiredoxin (Prx) system is a cellular defense system against oxidative stress, and mitochondria in cancer cells are known to contain high levels of Prx III. Here, we review accumulating evidence suggesting that mitochondrial oxidative stress is involved in cancer, and discuss the role of the mitochondrial Prx III antioxidant system as a potential target for cancer therapy. We hope that this review will provide the basis for new strategic approaches in the development of effective cancer treatments.
Keywords: ROS; mitochondria; peroxiredoxin III; cancer; antioxidant; oxidative stress; therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |

MDPI and ACS Style

Song, I.-S.; Kim, H.-K.; Jeong, S.-H.; Lee, S.-R.; Kim, N.; Rhee, B.D.; Ko, K.S.; Han, J. Mitochondrial Peroxiredoxin III is a Potential Target for Cancer Therapy. Int. J. Mol. Sci. 2011, 12, 7163-7185.

AMA Style

Song I-S, Kim H-K, Jeong S-H, Lee S-R, Kim N, Rhee BD, Ko KS, Han J. Mitochondrial Peroxiredoxin III is a Potential Target for Cancer Therapy. International Journal of Molecular Sciences. 2011; 12(10):7163-7185.

Chicago/Turabian Style

Song, In-Sung; Kim, Hyoung-Kyu; Jeong, Seung-Hun; Lee, Sung-Ryul; Kim, Nari; Rhee, Byoung Doo; Ko, Kyung Soo; Han, Jin. 2011. "Mitochondrial Peroxiredoxin III is a Potential Target for Cancer Therapy." Int. J. Mol. Sci. 12, no. 10: 7163-7185.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert